Want to see HK:2171 full AI Analyst Report?
Top Page
CARsgen Therapeutics Holdings Ltd.
(2171)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$11.00
▼(-25.52% Downside)
Action:Reiterated
Date:09/26/26
The score is held back primarily by persistent operating losses, significant ongoing cash burn, and declining equity despite improving revenue and gross profit. Technicals also remain weak with the stock trading below major moving averages and negative MACD. Valuation provides limited support due to negative earnings and no stated dividend yield.
Positive Factors
Revenue and gross profit growth
The sharp increase in revenue and first reported gross profit indicate improving commercial traction and better product economics. If this progress continues, it could provide a stronger base for funding development, supporting operating leverage and reducing dependence on external capital over time.
Negative Factors
Persistent operating losses
Despite stronger revenue and positive gross profit, CARsgen remains deeply loss-making at both operating and net-income levels. Continued losses indicate that current commercial progress does not yet cover research, development, and corporate costs, keeping earnings dependent on further investment and funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross profit growth
The sharp increase in revenue and first reported gross profit indicate improving commercial traction and better product economics. If this progress continues, it could provide a stronger base for funding development, supporting operating leverage and reducing dependence on external capital over time.
Read all positive factors
CARsgen Therapeutics Holdings Ltd. (2171) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.51B
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth68.12%
EPS Growth81.84%
CountryHK
Employees424
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding594,248,900
10 Day Avg. Volume1,393,122
30 Day Avg. Volume1,649,555
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)9.40
Price to Sales (P/S)58.60
P/FCF Ratio-30.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.82Price Target Upside-6.43% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)HK$288.56M
CARsgen Therapeutics Holdings Ltd. Business Overview & Revenue Model
Company Description
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts...
How the Company Makes Money
CARsgen’s primary way to generate revenue is through (1) product sales from any therapies that receive regulatory approval and are commercialized, where revenue is recognized from selling CAR-T products to hospitals/clinics and other qualified tre...
CARsgen Therapeutics Holdings Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 136.62M | 125.66M | 39.42M | 0.00 | 0.00 | 25.81M |
| Gross Profit | 92.60M | 79.95M | 14.75M | 0.00 | 0.00 | 25.81M |
| EBITDA | -191.43M | -198.40M | -482.66M | -697.65M | -724.11M | -534.95M |
| Net Income | -89.04M | -97.86M | -798.13M | -747.79M | -892.25M | -4.74B |
Balance Sheet | ||||||
| Total Assets | 1.58B | 1.29B | 1.67B | 2.26B | 2.76B | 3.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.40B | 1.12B | 1.48B | 1.85B | 2.27B | 3.01B |
| Total Debt | 71.98M | 61.20M | 166.42M | 85.22M | 119.44M | 338.05M |
| Total Liabilities | 486.94M | 513.02M | 616.33M | 455.51M | 289.64M | 508.98M |
| Stockholders Equity | 1.10B | 783.65M | 1.06B | 1.80B | 2.47B | 3.00B |
Cash Flow | ||||||
| Free Cash Flow | -186.66M | -243.03M | -429.26M | -464.48M | -781.66M | -690.77M |
| Operating Cash Flow | -174.63M | -228.44M | -409.69M | -454.94M | -643.05M | -512.32M |
| Investing Cash Flow | -9.62M | -2.88M | 12.52M | 39.25M | 2.39B | -2.47B |
| Financing Cash Flow | 336.67M | -111.72M | 18.46M | -22.14M | -236.51M | 2.67B |
CARsgen Therapeutics Holdings Ltd. Technical Analysis
Negative
14.77
Price Trends
12.56
Negative
13.73
Negative
15.60
Negative
Market Momentum
-0.45
Positive
37.94
Neutral
35.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2171, the sentiment is Negative. The current price of 14.77 is above the 20-day moving average (MA) of 11.73, above the 50-day MA of 12.56, and below the 200-day MA of 15.60, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 37.94 is Neutral, neither overbought nor oversold. The STOCH value of 35.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2171.
CARsgen Therapeutics Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | HK$22.08B | -12.93 | -27.40% | ― | 5.38% | 16.86% | |
52 Neutral | HK$929.65M | -2.37 | -66.16% | ― | 67.48% | 43.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$6.51B | -57.92 | -9.45% | ― | 68.12% | 81.84% | |
47 Neutral | HK$6.32B | -32.05 | -10.27% | ― | -31.77% | -177.01% | |
44 Neutral | HK$31.00B | -69.59 | -7.32% | ― | 34.83% | 58.94% | |
41 Neutral | HK$7.45B | -14.89 | -43.54% | ― | 116.67% | -0.42% |
* Healthcare Sector Average
HK:2171
CARsgen Therapeutics Holdings Ltd.
10.95
-5.53
-33.56%
HK:9688
Zai Lab Ltd
17.68
-2.42
-12.04%
HK:9966
Alphamab Oncology
6.49
-5.01
-43.57%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.88
-10.70
-40.26%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.23
-1.25
-35.92%
HK:2616
CStone Pharmaceuticals
4.74
-1.52
-24.36%
CARsgen Therapeutics Holdings Ltd. Corporate Events
CARsgen showcases new satri-cel data as it expands solid-tumor CAR T push
Oct 26, 2026
CARsgen Therapeutics Holdings Ltd., a biopharmaceutical company focused on CAR T-cell therapies for hematologic malignancies, solid tumors and autoimmune diseases, has established integrated research, clinical and manufacturing capabilities to sup...
CARsgen starts registrational trial for allogeneic CAR T therapy CT0596 in China
Oct 13, 2026
CARsgen Therapeutics Holdings Ltd. has dosed the first patient in a registrational Phase I clinical trial in China for CT0596, its allogeneic BCMA-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma. The treatment, built on the...
CARsgen Sets Out Board and Committee Structure
Sep 30, 2026
CARsgen Therapeutics Holdings Limited has announced the current composition of its board of directors, detailing the roles of executive, non-executive and independent non-executive members. The board is chaired by Dr. Zonghai Li, with six other di...
CARsgen faces temporary audit committee shortfall after non-executive director resigns
Sep 30, 2026
CARsgen Therapeutics Holdings Ltd., a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, operates with a diversified board that includes executive, non-executive and independent non-executive directors. Its governance frame...
CARsgen Starts First-Patient Dosing in China Registrational Trial for Allogeneic CAR T Therapy CT1190B
Sep 29, 2026
CARsgen Therapeutics Holdings has dosed the first patient with CT1190B, an allogeneic CAR T-cell product targeting CD19/CD20, in a registrational Phase I trial in China for relapsed or refractory large B-cell lymphoma after failure of at least two...
CARsgen narrows loss and boosts cash on CAR T sales and top-up placing
Aug 18, 2026
CARsgen Therapeutics reported interim results for the six months ended June 30, 2026, highlighting revenue of about RMB62 million, driven mainly by higher sales of zevorcabtagene autoleucel, and gross profit of roughly RMB42 million, supported by ...
CARsgen Wins NMPA IND Clearance for Allogeneic CAR T Therapy CT1190B in R/R Large B-Cell Lymphoma
Aug 7, 2026
CARsgen announced that its allogeneic CAR T-cell product CT1190B, which targets both CD19 and CD20, has received investigational new drug clearance from China’s National Medical Products Administration for use in patients with relapsed or re...
CARsgen Board Sets August Meeting to Approve 2026 Interim Results
Aug 6, 2026
CARsgen Therapeutics Holdings Ltd. has scheduled a board meeting for August 18, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026. The meeting will also address other corporate matters, signaling r...
CARsgen Wins NMPA IND Clearance for CT0596 in Multiple Myeloma
Aug 4, 2026
CARsgen Therapeutics announced that its allogeneic BCMA-targeted CAR T-cell product CT0596 has received Investigational New Drug clearance from China’s National Medical Products Administration for treating patients with relapsed or refractor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.